| CAS NO: | 69304-47-8 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| Cas No. | 69304-47-8 |
| 别名 | 溴夫定; Bromovinyldeoxyuridine; BVDU |
| Canonical SMILES | OC[C@@H]1[C@H](C[C@H](N2C(NC(C(/C=C/Br)=C2)=O)=O)O1)O |
| 分子式 | C11H13BrN2O5 |
| 分子量 | 333.14 |
| 溶解度 | DMSO : ≥ 330 mg/mL (990.57 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster. Brivudine is an analog of thymidine, and is incorporated into the viral DNA. It blocks the action of DNA polymerases, thus inhibiting viral replication. It has a stronger antiviral effect against the varicella-zoster virus compared with reference compounds such as aciclovir or penciclovir[1]. It has high, selective activity against varicella zoster virus (VZV), inhibiting VZV replication, possibly through competitive inhibition of viral DNA polymerase, or by acting as an alternative substrate to deoxythymidine triphosphate, causing viral DNA strand breakage[2]. At a dose of 125 mg once daily, brivudine has proved to be superior to aciclovir with respect to reducing the period of new blister production, and has shortened the duration of post-herpetic neuralgia[1]. [1]. Rabasseda X, et al. Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today (Barc). 2003 May;39(5):359-71. [2]. Keam SJ, et al. Brivudin (bromovinyl deoxyuridine). Drugs. 2004;64(18):2091-7; discussion 2098-9. |
m.cnreagent.com